These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 9793321

  • 1. [The treatment of chronic ischemic heart disease: the potentials for hypolipidemic correction using current drugs].
    Tashchuk VK, Makoviĭchuk IO, Bilets'kyĭ SV, Hrechko SI, Polishchuk OIu, Turubarova NA.
    Lik Sprava; 1998; (5):101-3. PubMed ID: 9793321
    [Abstract] [Full Text] [Related]

  • 2. Ciprofibrate and lipid profile.
    Chandler HA, Batchelor AJ.
    Lancet; 1994 Jul 09; 344(8915):128-9. PubMed ID: 7912363
    [No Abstract] [Full Text] [Related]

  • 3. Abnormal lipid profiles on fibrate derivatives.
    McLeod AJ, Warren RJ, Armitage M.
    Lancet; 1996 Jan 27; 347(8996):261. PubMed ID: 8551900
    [No Abstract] [Full Text] [Related]

  • 4. Lipid profiles on fibric-acid derivatives.
    Capps NE.
    Lancet; 1994 Sep 03; 344(8923):684-5. PubMed ID: 7915370
    [No Abstract] [Full Text] [Related]

  • 5. [A trial of the use of the hypolipidemic preparation Lipanor (ciprofibrate) in patients with primary hyperlipidemia].
    Kukharchuk VV, Rozhkova TA, Kotova LA, Tvorogova MG, Semenova OA.
    Ter Arkh; 1996 Sep 03; 68(6):58-61. PubMed ID: 8771689
    [Abstract] [Full Text] [Related]

  • 6. [The action of a fibric acid derivative on lipid metabolism].
    Filip M, Păduraru I, Nechifor M, Dănilă GH, Popovici I, Filip FM, Poşircă F.
    Rev Med Chir Soc Med Nat Iasi; 1989 Sep 03; 93(3):573-6. PubMed ID: 2636755
    [Abstract] [Full Text] [Related]

  • 7. [The new atherogenic plasma index reflects the triglyceride and HDL-cholesterol ratio, the lipoprotein particle size and the cholesterol esterification rate: changes during lipanor therapy].
    Dobiásová M, Frohlich J.
    Vnitr Lek; 2000 Mar 03; 46(3):152-6. PubMed ID: 11048517
    [Abstract] [Full Text] [Related]

  • 8. Impressive lipid changes following hypolipidaemic drug administration can unveil subclinical hyperthyroidism.
    Liberopoulos E, Miltiadous G, Elisaf M.
    Diabetes Obes Metab; 2001 Apr 03; 3(2):97-8. PubMed ID: 11298731
    [Abstract] [Full Text] [Related]

  • 9. [Antilipemic therapy in dyslipidemias in obese non-insulin-dependent diabetics (ONIDDM)].
    Palel G, Coman A, Petrovanu R, Ungureanu D, Cojocaru M.
    Rev Med Chir Soc Med Nat Iasi; 1997 Apr 03; 101(3-4):120-2. PubMed ID: 10756782
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Lipanor treatment of atherogenic hyperlipoproteinemia].
    Susekov AV, Tvorogova MG, Arabidze GG, Kukharchuk VV.
    Ter Arkh; 1998 Apr 03; 70(9):57-61. PubMed ID: 9821228
    [Abstract] [Full Text] [Related]

  • 12. [The effect of monotherapy with ciprofibrate and in combination with acetylsalicylic acid on the spectrum of lipids, thromboxane and fibrinogen in patients with atherosclerosis and hyperlipoproteinemia].
    Gajdos M, Fedelesova V, Mongiellova V, Cibulova L, Huttova D, Polak F, Krivosikova Z.
    Bratisl Lek Listy; 1999 Aug 03; 100(8):449-53. PubMed ID: 10645034
    [Abstract] [Full Text] [Related]

  • 13. [Treatment of familial combined hyperlipidemia].
    Bruckert E.
    Ann Endocrinol (Paris); 1997 Aug 03; 58(4):297-301. PubMed ID: 9436478
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Ciprofibrate versus gemfibrozil in the treatment of primary hyperlipidaemia.
    Knipscheer HC, de Valois JC, van den Ende B, Wouter ten Cate J, Kastelein JJ.
    Atherosclerosis; 1996 Jul 03; 124 Suppl():S75-81. PubMed ID: 8831919
    [Abstract] [Full Text] [Related]

  • 16. Paradoxical high-density lipoprotein reduction induced by fenofibrate and ciprofibrate.
    Collinson PO, Hjelm CJ, Canepo-Anson R.
    Ann Clin Biochem; 1996 Mar 03; 33 ( Pt 2)():159-61. PubMed ID: 8729728
    [No Abstract] [Full Text] [Related]

  • 17. Fibrates and HDL cholesterol.
    Murphy MJ, Packard CJ, O'Reilly DS.
    Ann Clin Biochem; 1997 Jan 03; 34 ( Pt 1)():114. PubMed ID: 9022900
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Ciprofibrate increases plasma concentration of platelet-derived growth factor AB in patients with advanced atherosclerosis and hyperlipidemia independently of its hypolipidemic effects.
    Gajdos M, Mongiellová V, Huttová D, Cibulová L, Krivosíková Z, Spustová V, Dzúrik R.
    J Cardiovasc Pharmacol; 2001 Nov 03; 38(5):651-6. PubMed ID: 11602811
    [Abstract] [Full Text] [Related]

  • 20. Effects of various fibrates on serum alkaline phosphatase activity.
    Ganotakis E, Tsimihodimos V, Bairaktari E, Rizos E, Athyros V, Seferiades C, Elisaf M.
    Atherosclerosis; 2002 Nov 03; 165(1):187-8. PubMed ID: 12208487
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.